Wells Fargo & Company Galecto, Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLTO
# of Institutions
29Shares Held
3.96MCall Options Held
30.6KPut Options Held
200-
Novo Holdings Hellerup, G72.5MShares$1.4 Million0.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny579KShares$324,2300.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA221KShares$123,8720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA208KShares$116,6660.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il93.5KShares$52,3600.0% of portfolio
About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $14.2M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...